CD8 ⁺ T cell targeting of tumor antigens presented by HLA-E.

Autor: Iyer RF; Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health and Science University, Beaverton, OR 97006, USA., Verweij MC; Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health and Science University, Beaverton, OR 97006, USA., Nair SS; Department of Urology and Tisch Cancer Institute, Icahn School of Medicine at Mt Sinai, New York, NY 10029, USA., Morrow D; Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health and Science University, Beaverton, OR 97006, USA., Mansouri M; Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health and Science University, Beaverton, OR 97006, USA., Chakravarty D; Department of Urology and Tisch Cancer Institute, Icahn School of Medicine at Mt Sinai, New York, NY 10029, USA., Beechwood T; Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health and Science University, Beaverton, OR 97006, USA., Meyer C; Vir Biotechnology, San Francisco, CA 14158, USA., Uebelhoer L; Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health and Science University, Beaverton, OR 97006, USA., Lauron EJ; Vir Biotechnology, San Francisco, CA 14158, USA., Selseth A; Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health and Science University, Beaverton, OR 97006, USA., John N; Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health and Science University, Beaverton, OR 97006, USA., Thin TH; Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA., Dzedzik S; Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA., Havenar-Daughton C; Vir Biotechnology, San Francisco, CA 14158, USA., Axthelm MK; Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health and Science University, Beaverton, OR 97006, USA., Douglas J; Vir Biotechnology, San Francisco, CA 14158, USA., Korman A; Vir Biotechnology, San Francisco, CA 14158, USA., Bhardwaj N; Department of Urology and Tisch Cancer Institute, Icahn School of Medicine at Mt Sinai, New York, NY 10029, USA.; Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA., Tewari AK; Department of Urology and Tisch Cancer Institute, Icahn School of Medicine at Mt Sinai, New York, NY 10029, USA., Hansen S; Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health and Science University, Beaverton, OR 97006, USA., Malouli D; Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health and Science University, Beaverton, OR 97006, USA., Picker LJ; Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health and Science University, Beaverton, OR 97006, USA., Früh K; Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health and Science University, Beaverton, OR 97006, USA.

Publikováno v: Science advances [Sci Adv] 2024 May 10; Vol. 10 (19), pp. eadm7515. Date of Electronic Publication: 2024 May 10.

Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms.

Autor: Tortorici MA; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.; Institut Pasteur and CNRS UMR 3569, Unité de Virologie Structurale, Paris, France., Beltramello M; Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland., Lempp FA; Vir Biotechnology, San Francisco, CA 94158, USA., Pinto D; Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland., Dang HV; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA., Rosen LE; Vir Biotechnology, San Francisco, CA 94158, USA., McCallum M; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA., Bowen J; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA., Minola A; Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland., Jaconi S; Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland., Zatta F; Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland., De Marco A; Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland., Guarino B; Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland., Bianchi S; Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland., Lauron EJ; Vir Biotechnology, San Francisco, CA 94158, USA., Tucker H; Vir Biotechnology, San Francisco, CA 94158, USA., Zhou J; Vir Biotechnology, San Francisco, CA 94158, USA., Peter A; Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland., Havenar-Daughton C; Vir Biotechnology, San Francisco, CA 94158, USA., Wojcechowskyj JA; Vir Biotechnology, San Francisco, CA 94158, USA., Case JB; Departments of Medicine, Molecular Microbiology, Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA., Chen RE; Departments of Medicine, Molecular Microbiology, Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA., Kaiser H; Vir Biotechnology, San Francisco, CA 94158, USA., Montiel-Ruiz M; Vir Biotechnology, San Francisco, CA 94158, USA., Meury M; Vir Biotechnology, San Francisco, CA 94158, USA., Czudnochowski N; Vir Biotechnology, San Francisco, CA 94158, USA., Spreafico R; Vir Biotechnology, San Francisco, CA 94158, USA., Dillen J; Vir Biotechnology, San Francisco, CA 94158, USA., Ng C; Vir Biotechnology, San Francisco, CA 94158, USA., Sprugasci N; Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland., Culap K; Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland., Benigni F; Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland., Abdelnabi R; Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, KU Leuven, Belgium., Foo SC; Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, KU Leuven, Belgium., Schmid MA; Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland., Cameroni E; Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland., Riva A; III Division of Infectious Diseases, Luigi Sacco University Hospital, University of Milan, Italy., Gabrieli A; III Division of Infectious Diseases, Luigi Sacco University Hospital, University of Milan, Italy., Galli M; III Division of Infectious Diseases, Luigi Sacco University Hospital, University of Milan, Italy., Pizzuto MS; Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland., Neyts J; Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, KU Leuven, Belgium., Diamond MS; Departments of Medicine, Molecular Microbiology, Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA., Virgin HW; Vir Biotechnology, San Francisco, CA 94158, USA.; Washington University School of Medicine, St. Louis, MO, USA.; UTSouthwestern Medical Center, Dallas, TX, USA., Snell G; Vir Biotechnology, San Francisco, CA 94158, USA., Corti D; Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland., Fink K; Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. dveesler@uw.edu katja.fink@alumni.ethz.ch., Veesler D; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA. dveesler@uw.edu katja.fink@alumni.ethz.ch.

Publikováno v: Science (New York, N.Y.) [Science] 2020 Nov 20; Vol. 370 (6519), pp. 950-957. Date of Electronic Publication: 2020 Sep 24.

Viral MHCI inhibition evades tissue-resident memory T cell formation and responses.

Autor: Lauron EJ; Division of Rheumatology, Department of Medicine, Washington University School of Medicine, St. Louis, MO., Yang L; Division of Rheumatology, Department of Medicine, Washington University School of Medicine, St. Louis, MO., Harvey IB; Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO., Sojka DK; Division of Rheumatology, Department of Medicine, Washington University School of Medicine, St. Louis, MO., Williams GD; Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO., Paley MA; Division of Rheumatology, Department of Medicine, Washington University School of Medicine, St. Louis, MO., Bern MD; Division of Rheumatology, Department of Medicine, Washington University School of Medicine, St. Louis, MO., Park E; Division of Rheumatology, Department of Medicine, Washington University School of Medicine, St. Louis, MO., Victorino F; Division of Rheumatology, Department of Medicine, Washington University School of Medicine, St. Louis, MO., Boon ACM; Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO.; Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO., Yokoyama WM; Division of Rheumatology, Department of Medicine, Washington University School of Medicine, St. Louis, MO yokoyama@wustl.edu.; Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO.

Publikováno v: The Journal of experimental medicine [J Exp Med] 2019 Jan 07; Vol. 216 (1), pp. 117-132. Date of Electronic Publication: 2018 Dec 17.

Cross-priming induces immunodomination in the presence of viral MHC class I inhibition.

Autor: Lauron EJ; Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, United States of America., Yang L; Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, United States of America., Elliott JI; Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri, United States of America., Gainey MD; Department of Biology, Western Carolina University, Cullowhee, North Carolina, United States of America., Fremont DH; Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri, United States of America.; Department of Biochemistry and Molecular Biophysics, Washington University School of Medicine, St. Louis, Missouri, United States of America.; Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, Missouri, United States of America., Yokoyama WM; Division of Rheumatology, Washington University School of Medicine, St. Louis, Missouri, United States of America.

Publikováno v: PLoS pathogens [PLoS Pathog] 2018 Feb 14; Vol. 14 (2), pp. e1006883. Date of Electronic Publication: 2018 Feb 14 (Print Publication: 2018).

Rhoptry Proteins ROP5 and ROP18 Are Major Murine Virulence Factors in Genetically Divergent South American Strains of Toxoplasma gondii.

Autor: Behnke MS; Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, Missouri, United States of America., Khan A; Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, Missouri, United States of America., Lauron EJ; Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, Missouri, United States of America., Jimah JR; Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, Missouri, United States of America., Wang Q; Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, Missouri, United States of America., Tolia NH; Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, Missouri, United States of America., Sibley LD; Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, Missouri, United States of America.

Publikováno v: PLoS genetics [PLoS Genet] 2015 Aug 20; Vol. 11 (8), pp. e1005434. Date of Electronic Publication: 2015 Aug 20 (Print Publication: 2015).